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Renal angiomyolipomas (AML) contain an admixture of clonal tumour cells with features of
several different mesenchymal lineages, implying the existence of an unidentiﬁed AML
neoplastic stem cell. Biallelic inactivation of TSC2 or TSC1 is believed to represent the driving
event in these tumours. Here we show that TSC2 knockdown transforms senescence-
resistant cultured mouse and human renal epithelial cells into neoplastic stem cells that
serially propagate renal AML-like tumours in mice. mTOR inhibitory therapy of mouse AML
allografts mimics the clinical responses of human renal AMLs. Deletion of Tsc1 in mouse renal
epithelia causes differentiation in vivo into cells expressing characteristic AML markers.
Human renal AML and a renal AML cell line express proximal tubule markers. We describe
the ﬁrst mouse models of renal AML and provide evidence that these mesenchymal tumours
originate from renal proximal tubule epithelial cells, uncovering an unexpected pathological
differentiation plasticity of the proximal tubule.
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Renal angiomyolipomas (AML) are benign, but life-threatening neoplasms that contain variable admixturesof tumour cells that are histologically and molecularly
similar to vascular (angio-), smooth muscle (myo-) and fat (lipo-)
lineages1. Genetic analyses have shown that these different cell
types within an individual AML are clonal2,3, indicating that they
must be derived from a common tumour-initiating cell that has
the capacity to differentiate into these different lineages, sugges-
tive of a putative neoplastic stem cell. However, the identities and
characteristics of the normal cell of origin of AML and of the
presumptive AML stem cell remain unknown. Renal AML cells
also express molecular markers of the melanocyte lineage4,5,
which serve as clinical diagnostic markers. As embryonic neural
crest stem cells or neural crest-derived progenitor cells from the
adult skin can differentiate to form melanocytes, adipocytes and
smooth muscle cells6–8, the cell type of origin of renal AML has
been proposed to be an unidentiﬁed kidney-resident, neural crest-
derived lineage5. Others have suggested that myoblasts9, peri-
cytes10 or lymphatic endothelium11 represent the AML cell of
origin. It is also possible that another renal cell type could become
transformed and reprogrammed to form a neoplastic AML stem
cell. In this context is noteworthy that a rare variant of AML,
called AMLEC (AML with epithelial cysts) contains epithelial
tubular or cystic structures12. While it has not yet been con-
clusively proven, there is some evidence that these epithelial
structures may be tumour-derived13,14, implying that the putative
AML or AMLEC neoplastic stem cell may also have the capacity
to differentiate into renal epithelial cells in some cases.
Multiple and bilateral renal AMLs develop in up to 80% of
patients with the autosomal dominant tuberous sclerosis complex
(TSC) syndrome (also known as Bourneville–Pringle disease),
affecting ~1 in 6,000 newborns4. AMLs represent the most
common cause of mortality in adult TSC patients due to spon-
taneous haemorrhage of abnormal tumour vasculature and can
also cause signiﬁcant morbidity by compressing adjacent normal
kidney tissue, thereby impairing kidney function. TSC patients
inherit a loss of function mutation in one allele of either of the
TSC1 or TSC2 genes and AMLs in these patients almost always
display somatic mutation of the wild type allele15–17. Roughly
80% of all renal AMLs arise sporadically in the general popula-
tion, affecting ~0.6% of females and 0.3% of males18. These
tumours also almost invariably display biallelic loss of TSC2 or
more rarely of TSC115–17,19. The TSC1 (also known as
HAMARTIN) and TSC2 (also known as TUBERIN) proteins
form a complex that negatively regulates the mTORC1 protein
kinase complex, a key node in cellular signalling networks that
control cellular growth and proliferation. Consistent with the
oncogenic role of constitutive mTORC1 activation, everolimus,
an inhibitor of mTORC1, causes regression of renal AMLs in
many patients20 and this therapy isapproved by the U.S. Food
and Drug Administration and the European Medicines Agency
for the treatment of TSC-associated renal AML. Despite the clear
role of TSC1 and TSC2 mutation in the human disease, renal
AMLs surprisingly did not develop in numerous mouse models
involving homozygous or heterozygous deletion of Tsc1 or Tsc2
(reviewed in ref.21). However, inducible, ubiquitous Cre-mediated
deletion of Tsc1 caused the development of small kidney lesions
displaying several characteristic renal AML markers such as
HMB45, Smooth Muscle Actin (SMA), CATHEPSIN K and
VIMENTIN22, suggesting that these lesions might represent renal
AML precursor lesions. The cell type that gave rise to these
lesions was not determined.
In this study we utilised a reverse tumour-engineering
approach in mouse and human cells to explore the cell of ori-
gin of renal AML. Surprisingly we identiﬁed that our renal AML
tumour models derive from renal epithelial cells. We further
showed that some cells in human renal AMLs, as well as a renal
AML cell line, exhibit molecular features of renal proximal tub-
ular epithelial cells. These ﬁndings argue that renal AMLs might
derive from proximal tubule epithelial cells.
Results
Tsc2 and Cdkn2a loss converts renal cells into AML-forming
cells. As renal AMLs are relatively genetically simple tumours
that are characterised almost exclusively by recurrent TSC2 or
TSC1 mutations19, we reasoned that it might be possible to
reverse engineer renal AML starting from normal primary cells.
We ﬁrst utilised primary mouse embryo ﬁbroblasts (MEFs) to
establish RNAi tools to knockdown Tsc1 and Tsc2. Infection with
lentiviruses expressing shRNA-Tsc1 or shRNA-Tsc2 efﬁciently
reduced TSC1 or TSC2 protein abundance, increased phosphor-
ylation of ribosomal protein S6 (Ser240/244) and 4E-BP1 (Thr37/
46), indicative of mTORC1 activation, and caused accumulation
of HIF-1α and the HIF-1α inducible protein GLUT1 (Supple-
mentary Fig. 1a), mimicking previously published effects of
knockout of Tsc1 or Tsc2 in MEFs23–25. Tsc1 or Tsc2 knockdown
also inhibited cellular proliferation and induced premature
senescence (Supplementary Fig. 1b, c), another known con-
sequence of loss of function of TSC1 or TSC224,25.
As the cell type of origin of renal AML is unknown, we
prepared primary cultures from collagenase-digested whole
mouse kidneys with the aim of simultaneously isolating different
types of kidney cells and cultured them in renal epithelial cell
medium. These cultures predominantly comprised E-
CADHERIN-expressing epithelial cells with rare VIMENTIN-
expressing cells (Supplementary Fig. 2a, b). Knockdown of Tsc1
or Tsc2 in these cultures also caused rapid loss of proliferative
capacity (data not shown). Knockdown of TSC2 in primary
human renal proximal tubular epithelial cells similarly caused
inhibition of proliferation and the ﬂattened, spread cellular
morphology that is characteristic of cellular senescence (data not
shown). This loss of proliferative capacity, a common conse-
quence of expression of oncogenes or loss of tumour suppressor
genes in primary cell culture systems, represents a limitation to an
ex vivo tumour engineering approach.
To overcome this problem we identiﬁed that Cdkn2a knockout
in MEFs rescued senescence and induced cellular transformation
upon knockdown of Tsc1 or Tsc2 (Supplementary Fig. 1d–i).
Using this information we ﬁrst observed that while cultures from
wild type kidneys lost epithelial appearance upon passaging,
cultures from Cdkn2aﬂ/ﬂ mice infected with a Cre-expressing
adenoviral vector to delete Cdkn2a (hereafter designated
Cdkn2aΔ/Δ cells) maintained epithelial appearance, proliferated
in culture (Fig. 1a) and formed colonies when plated at low
density on plastic but did not form colonies in soft agar (Fig. 1a
and Supplementary Fig. 2d). Infection of cultured Cdkn2aΔ/Δ
renal cells with lentiviruses expressing shRNA-Tsc1 or shRNA-
Tsc2 increased the rate of proliferation (Fig. 1a) and allowed the
formation of colonies in soft-agar (Fig. 1a and Supplementary
Fig. 2d), indicative of cellular transformation. Similarly, infection
of cultured renal cells from wild type mice with a lentiviral vector
expressing both shRNA-Tsc2 and shRNA-Cdkn2a (shRNA-Tsc2
+ Cdkn2a) (Supplementary Fig. 2c) increased proliferation rate
compared with shRNA-Cdkn2a knockdown and allowed growth
in soft agar (Fig. 1b and Supplementary Fig. 2e). Tsc2 knockdown
or Cdkn2a knockdown or knockout alone did not cause cellular
transformation (Fig. 1a, b), demonstrating the cooperativity of
this genetic effect. Genotypes that grew in soft agar acquired the
stem cell-like characteristic of growth as non-adherent spheres
that could be serially passaged (Fig. 1c). Approximately 9% of
cells from the total virus-infected cellular populations formed
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spheres. Importantly, when injected subcutaneously into female
SCID-beigemice, shRNA-Tsc2/Cdkn2aΔ/Δ (n= 12 injections) and
shRNA-Tsc2 + Cdkn2a (n= 16 injections) sphere-selected cells
formed slowly growing tumours within 1–2 months (Fig. 1d).
Tumours did not grow in male mice, potentially consistent with
the increased incidence of human renal AMLs in females
compared to males18. Allograft tumours showed several histolo-
gical similarities to human renal AML and comprised a mixture
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Fig. 1 An ex vivo genetically engineered model of renal AML. a Proliferation assay, western blot and soft-agar assay of Cdkn2aΔ/Δ primary kidney cells
following infection with lentiviruses expressing an empty shRNA (shRNA-Ctrl) or shRNAs against Tsc1 (shRNA-Tsc1) or Tsc2 (shRNA-Tsc2). b Proliferation
assay, western blot and soft-agar assay of primary kidney cells infected with lentiviruses expressing shRNAs against Cdkn2a (shRNA-Cdkn2a) or Tsc2 and
Cdkn2a (shRNA-Tsc2 + Cdkn2a). All graphs depict mean± s.d. Student’s t test, n= 3. ∗P< 0.05, ∗∗P< 0.01, ∗∗∗P< 0.001. c Phase contrast images of
spheres formed in suspension culture conditions from shRNA-Tsc2/Cdkn2aΔ/Δ and shRNA-Tsc2 + Cdkn2a primary kidney cells. Scale bars: 50 μm. d
Representative allografttumours derived from subcutaneous injections of respective sphere cells into SCID-beige mice.Scale bars: 1 cm. e Representative
histology of allograft renal AML-like tumours. Characteristic histological features of AML are indicated by letters, where A shows adipocyte, S shows
spindle cells and V shows an aberrant blood vessel. Epithelial structures are indicated by Ep. Scale bars: 50 μm. f Positive immunoﬂuorescence or
immunohistochemical staining in engineered renal AML-like allograft tumours for PMEL(HMB45), HMB45/MART-1, CATHEPSIN K, SMA, VIMENTIN,
PDGFRβ, CD31 and S100. Scale bars: 50 μm
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of mature adipose tissue, scattered blood vessels and spindle
shaped cells (Fig. 1e). Many tumours additionally exhibited some
epithelial tubular or cystic structures (Fig. 1e), although these
made up only a very small component of the entire tumour. At
the ultrastructural level, allograft tumours exhibited an expanded
endoplasmic reticulum (Supplementary Fig. 3a–d) that is
reminiscent of the expanded endoplasmic reticulum seen in
human renal AML tumours26. Importantly, regions of adipocyte
differentiation and spindle cells were immunoreactive for an
antibody cocktail that recognises the melanocyte markers HMB45
and MART-1, for the melanocyte protein PMEL (the HMB45
antigen), SMA and VIMENTIN (Fig. 1f), reproducing the
molecular characteristics that serve as diagnostic criteria for
human renal AML. Approximately 15% of cells in our allograft
tumours exhibited immunoreactivity for PMEL (Supplementary
Fig. 3e). While the majority of cells in human renal AMLs
typically stain strongly and diffusely for CATHEPSIN K27, our
allograft tumours exhibited a weak diffuse cytoplasmic positivity
with ~10% of cells exhibiting strong immunoreactivity for
CATHEPSIN K (Fig. 1f). mRNA analysis demonstrated high
levels of expression of the melanocyte genes Pmel, Tyrp1, Ctsk
(encoding CATHEPSIN K) and Mlana (also known as Mart1,
encoding the MART-1 antigen) in allografts compared to normal
kidney (Supplementary Fig. 3g) and western blotting conﬁrmed
that allograft tumours expressed both PMEL and CATHEPSIN K
(Supplementary Fig. 3h, i). Similarly to human renal AMLs,
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Fig. 2 Cells from Tsc2/Cdkn2adeﬁcient spheres exhibit stem cell-like characteristics. a shRNA-Tsc2/Cdkn2aΔ/Δ spheres were cultured in speciﬁc epithelial-,
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t test, n= 3. ∗ P< 0.05, ∗∗ P< 0.01. c Experimental overview of the generation of clonal cell lines (Sphere Clone 1–6 (SC1–6)). d Two independent sphere
clones (SC2 and SC4) were cultured in speciﬁc adipocyte- and neural crest-differentiation media and stained immunoﬂuorescently using antibodies against
PMEL (HMB45), GFAP or SMA or stained with Oil-Red-O. Scale bars: 50 μm.Analyses of two additional sphere clones (SC3 and SC6) are shown in
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the allograft tumour cells were negative for the endothelial cell
marker CD31, which instead labelled scattered dysmorphic blood
vessels in the tumours (Fig. 1f). Human renal AMLs have been
shown to harbour numerous cells that express PDGFRβ10 and
allograft tumours exhibited a similar staining pattern (Fig. 1f).
Human renal AMLs stain positively for the neural stem cell
marker NG228 and our allograft tumours similarly exhibited
diffuse NG2 immunoreactivty (Supplementary Fig. 4a). While
mature normal adipocytes stain positively for S100, adipocytes in
human renal AMLs typically do not express S100, but other non-
adipocyte components of the tumour have been reported to stain
positively in about 28% of renal AML cases29. Consistent with
this, in our allograft tumours, adipocytes stained negatively for
S100 and spindle shaped cells stained positively (Fig. 1f). In
summary, these ex vivo genetically engineered cells derived from
a kidney-resident cell type represent an allograft model that
shares many histological and molecular features with human
renal AML or AMLEC.
We next sought to determine whether the AML-like tumour
and cellular phenotypes observed in our system are speciﬁcally
related to the Tsc2 and Cdkn2a loss-of-function genotype or
whether any genetic combination that causes transformation and
sphere formation would give similar results. In the context of
another research project that will be described in detail elsewhere,
we discovered that the overexpression of the Myc oncogene in
Adeno-Cre-treated renal cell cultures derived from Trp53ﬂ/ﬂ mice
(Myc/Trp53Δ/Δ) causes the formation of spheres and these cells
form tumours in allograft assays (Supplementary Fig. 4c–f). In
contrast to the Tsc2/Cdkn2a AML-like tumours, Myc/Trp53Δ/Δ
allograft tumours grew as solid masses of epithelial-like cells,
sometimes organised in a pseudo-acinar pattern. Tumour cells
typically had low cytoplasmic volumes with enlarged prominent
nuclei. No histological similarities with renal AML were evident
and tumours showed no immunoreactivity for PMEL (Supple-
mentary Fig. 3e, f), S100 or NG2 (Supplementary Fig. 4a, b).
These ﬁndings further support the speciﬁcity of the effect of Tsc2
loss-of-function in our engineered renal AML model system.
AML-forming cells have neoplastic stem cell properties. Given
that AML-like tumours derived from our engineered cells com-
prise multiple different types of cells, as well as the previous
proposal that AMLs arise from a neural crest-derived cell type5,
we cultured shRNA-Tsc2/Cdkn2aΔ/Δ sphere cells in speciﬁc
adipocyte-, osteoblast-, neural crest- and epithelial- differentia-
tion media to assess their capacity to form different cellular
lineages in culture. Cells from spheres could be differentiated into
cells that expressed markers of adipocytes (Nile Red and Oil-red-
O staining), glia (GFAP), neurons (TUBULIN-β3), melanocytes
(HMB45/MART-1), smooth muscle cells (SMA) and epithelial
cells (E-CADHERIN) (Fig. 2a). The observation of a melanocyte-
like phenotype was supported by the fact that shRNA-Tsc2 +
Cdkn2a sphere cells that were differentiated in neural-crest dif-
ferentiation medium showed similar positive staining for
CATHEPSIN K, PMEL, MITF and MART-1 to the B16F1 mel-
anoma cell line (Supplementary Fig. 5). Our ﬁndings based on
stainings were supported by mRNA expression analyses (Fig. 2b)
showing that adipocyte differentiation medium induced expres-
sion of the adipocyte-speciﬁc gene Lpl, osteoblast differentiation
medium induced expression of the osteoblast-speciﬁc genes Sp7
and Bglap and neural crest differentiation medium induced the
expression of the glial-speciﬁc gene Gfap and neuron-speciﬁc
gene Tubb3. Undifferentiated spheres exhibit high levels of
expression of epithelial-speciﬁc genes (see later results) including
Kap and Vil1, which remained elevated when cultured in epi-
thelial differentiation medium but were greatly reduced when
cultured in the other differentiation media. To further demon-
strate the speciﬁcity of this phenotype we differentiated shRNA-
Tsc2 + Cdkn2a spheres in parallel with cultures of shRNA-
Cdkn2a kidney cells (which do not form spheres) and cultures
from Myc/Trp53Δ/Δ sphere cells. Only the shRNA-Tsc2 + Cdkn2a
spheres but not the two negative control cell lines could be dif-
ferentiated into Nile Red or PMEL positive cells (Supplementary
Fig. 6a) nor did the differentiated cultures upregulate any of the
adipocyte, osteoblast or neural-crest lineage speciﬁc genes that are
induced upon differentiation of shRNA-Tsc2 + Cdkn2a spheres
(Supplementary Fig. 6b). The two negative control cell lines also
showed no expression of PMEL by western blotting (Supple-
mentary Fig. 6c).
To determine whether single cells within spheres have the stem
cell characteristic of being able to differentiate into these multiple
cellular lineages we disrupted cells from individual shRNA-Tsc2/
Cdkn2aΔ/Δ spheres and plated them as single cells. These single
cells generated new spheres within 10 days and these were
passaged to form clonal cell lines (termed SC1- SC6) (Fig. 2c).
Four of six independent single cell-derived clonal lines derived
from three independent starting spheres possessed the ability to
differentiate into osteoblasts, adipocytes, glia and melanocytes in
culture, assessed using stainings (Fig. 2d and Supplementary
Fig. 7a) and mRNA expression (Supplementary Fig. 7b). These
four clones also formed characteristic AML tumours in in vivo
allograft assays (six tumours from six injections of each clone)
(Fig. 2e and Supplementary Fig. 7c), showing regions of adipocyte
differentiation, spindle cells, blood vessels and epithelial struc-
tures. These tumours showed similar patterns of immunoreacti-
vityto tumours obtained from whole sphere populations when
stained with antibodies against PMEL, SMA, PDGFRβ, CATHE-
PSIN K, NG2 and S100, as well as displayed E-CADHERIN
positive epithelial structures (Fig. 2e and Supplementary Figs. 4a,
b and 7c). The frequency of PMEL-positive cells in allograft
tumours was similar to the frequency seen in allograft tumours
from whole populations of spheres (Supplementary Fig. 3f).
Allograft tumours from SC2 and SC4 express melanocyte genes
(Supplementary Fig. 3g) and the proteins PMEL, MiTF and
CATHEPSIN K (Supplementary Fig. 7d). These results demon-
strate that single cells from our reverse-engineered sphere cell
populations have properties of tumour-forming AML stem cells
that have the ability to differentiate into several neural crest-
derived and mesenchymal cellular lineages, as well as into
epithelial cells. Interestingly, two of the six clones (SC1, SC5) did
not form tumours in allograft experiments (zero tumours from
six injections of each clone). These cells could be differentiated
into Nile Red-positive and SMA-positive cells in appropriate
media, but could not be differentiated into PMEL- or GFAP-
expressing cells (Supplementary Fig. 7e), demonstrating that not
all cells within a sphere have the properties of AML neoplastic
stem cells, potentially implying the existence of a hierarchy of
differentiation.
Given this mesenchymal differentiation phenotype we next
analysed markers of mesenchymal stem cells in our engineered
sphere cells. Flow cytometric comparisons of sphere-selected
shRNA-Tsc2/Cdkn2aΔ/Δ cells and control Cdkn2aΔ/Δ kidney
cells (Supplementary Fig. 8a) revealed that both genotypes of
sphere cells expressed SCA-1 and CD29, and shRNA-Tsc2/
Cdkn2aΔ/Δ cells speciﬁcally expressed the general mesenchymal
marker CD73, but none of the cells expressed other characteristic
markers of mesenchymal stem cells (CD105, CD106). These
ﬁndings argue against the idea that we have simply isolated a
normal population of kidney-resident mesenchymal stem cells
that represent the AML-forming sphere cells in our culture
system. The absence of expression of Nanog, Sox2 and Oct4,
which are abundantly expressed in ES cells (Supplementary
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Fig. 8b), also argues against an induced pluripotent stem cell
phenotype of our engineered sphere cells.
Neoplastic AML stem cells derive from renal epithelial cells. To
gain further insight into molecular features of the engineered
AML-initiating cells we used RNA sequencing to compare gene
expression between primary renal cell cultures 5 days after
infection with control or shRNA-Tsc2 + Cdkn2a viruses and
spheres derived from shRNA-Tsc2 + Cdkn2a-infected cells har-
vested 12 days after infection (Fig. 3a). Gene expression values are
provided in Supplementary Data 1. Compared with control
infected cells, total populations of shRNA-Tsc2 + Cdkn2a cells
displayed 154 genes that were upregulated >8-fold. Gene set
enrichment analyses (GSEA) revealed association with expression
signatures related to cellular proliferation and mTOR signalling
(Supplementary Data 2), consistent with the introduced knock-
downs and elevated proliferation rate of these cultures. Com-
parison of shRNA-Tsc2 + Cdkn2a spheres to shRNA-Tsc2 +
Cdkn2a total cell populations (similar results were obtained when
comparing shRNA-Tsc2 + Cdkn2a spheres to control infected
cells, data not shown) identiﬁed 584 genes that were >8-fold
upregulated in spheres (Supplementary Data 1). Interestingly, 93
of these genes overlapped with a set of 324 genes that are
expressed at 10-fold or higher levels in S1 or S3 segments of
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proximal tubules compared with distal tubules, loops of Henle
and collecting ducts30 (Fig. 3b). In contrast, comparison with a
cumulated list of 593 genes that are speciﬁcally upregulated either
in distal tubules, loops of Henleor collecting ducts compared to
proximal tubules30 revealed an overlap of only 7 genes (Fig. 3b).
The upregulation of a subset of the identiﬁed proximal tubule-
speciﬁc genes (Slc34a1, Slc13a3, Aqp1, Vil1, Cubn, Fmo1, Kap) in
spheres compared with total shRNA-Tsc2/sh+Cdkn2a popula-
tions was conﬁrmed by real time PCR analyses (Fig. 3c). This
result surprisingly demonstrates that spheres exhibit a stronger
renal proximal tubule epithelial gene expression signature than
cultured primary renal epithelial cells. Further supporting the
epithelial nature of the spheres, Hnf4a was upregulated ~10,000
fold in spheres (Fig. 3c). Hnf4a encodes a transcription factor that
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is necessary for development of renal proximal tubules, is highly
expressed in proximal tubule epithelial cells and regulates the
expression of numerous proximal tubule speciﬁc genes31,32.
GSEA analyses also identiﬁed experimentally established HNF4A
and HNF1A target genes (Supplementary Data 2) and genes with
bioinformatically predicted HNF4A and HNF1A transcription
factor binding sites (Supplementary Data 2) as being signiﬁcantly
enriched in the sphere gene set. Genes encoding 14 different
transcription factors that have been implicated in the develop-
ment of many different cellular lineages were also upregulated
>8-fold in spheres (Supplementary Data 1) and 3 of these (Hnf4a,
Tal1, Tfec) were conﬁrmed by real time PCR analyses (Fig. 3c).
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These proximal tubule and transcription factor gene signatures
were also present in the four clonal sphere lines and in AML
allograft tumours (Fig. 3c), suggesting that the engineered
tumours display at least some of the characteristic gene expres-
sion proﬁle of the proximal tubule epithelial cell, arguing that
proximal tubular epithelial cells are the origin of these engineered
tumours. Further supporting this notion, some cells in spheres
expressed NAPI2A or stained positively for pan-CD133 (not the
glycosylation-speciﬁc ‘stem cell marker’ antibody) (Fig. 3d),
which are expressed by normal renal proximal tubule epithelial
cells. At the same time, shRNA-Tsc2 + Cdkn2a spheres also
exhibited evidence of an AML or melanocyte-like phenotype as
shown by immunoreactivity for the AML markers PMEL,
CATHEPSIN K, MiTF and MART-1 (Fig. 3d), expression of
MiTF and CATHEPSIN K by western blotting (Supplementary
Fig. 9a) and upregulation of Tyrp1 gene expression in comparison
to non-sphere populations or to Myc/Trp53Δ/Δ sphere popula-
tions (Supplementary Fig. 9b). Spindle cells in allograft AML
tumours (Fig. 3e) also expressed the proximal tubule marker
protein NAPI2A and epithelial structures in these tumours were
positive for the epithelial markers E-CADHERIN and PAN-
CYTOKERATIN and stained positively for pan-CD133, RCC and
CD10 (Fig. 3e), three markers of the renal proximal tubule epi-
thelium. We conclude that AML-forming sphere cells can also
differentiate into proximal tubule epithelial cells. Consistent with
a renal epithelial phenotype, scattered cells in allograft tumours
derived from total sphere populations or from sphere clonal cell
lines expressed the transcription factor PAX8, which is normally
expressed in epithelia of the renal and genital-urinary tract
(Supplementary Fig. 9c).
To gain further evidence for an epithelial origin of our
engineered tumours we next genetically marked renal epithelial
cells in vivo, labelling all nephron segments by doxycycline
feeding of mice harbouring transgenes encoding Pax8 promoter-
regulated expression of rtTA, Tet-responsive Cre expression33
and ROSA26-lox-STOP-lox-regulated tdTomato expression34
(Pax8-rtTA;TRE-LC1;R26R-LSL-tdTomato) (Fig. 4a). In total
85% of cells cultured from these kidneys were tdTomato-
positive (Fig. 4b) and when transformed with shRNA-Tsc2 +
Cdkn2a lentiviruses 90% of the resulting spheres were tdTomato-
positive (Fig. 4c). These could be differentiated to form
tdTomato-positive epithelial cells, adipocytes and glia (Fig. 4d)
and expressed characteristic genes of differentiated lineages
(Supplementary Fig. 6b). Negative staining controls are shown
in Supplementary Fig. 10a–d. Allograft tumours derived from
these cultures expressed tdTomato (Fig. 4e) and cells in tumour
regions characterised by adipocyte, spindle cell and thick-walled
blood vessel histology were labelled with tdTomato (Fig. 4f).
Similarly to the other tumours generated in this study, these
allograft tumours stained positively for PMEL, CATHEPSIN K,
PDGFRβ, SMA and VIMENTIN (Supplementary Fig. 10e),
expressed PMEL by western blotting (Supplementary Fig. 10f),
and exhibited a similar frequency of PMEL expressing cells
(Supplementary Fig. 10g).
Cells isolated by collagenase digestion of resected tumours
could be cultured as tdTomato-expressing spheres and sphere-
selected cells formed new tdTomato-positive allograft AML
tumours (Fig. 4g), establishing that these cells have tumour-
propagating capacity, an expected feature of a neoplastic tumour
stem cell. In contrast, in vivo lineage tracing of neural crest-
derived cells using Sox10-Cre;R26R-LSL-tdTomato mice labelled a
set of non-tubular interstitial cells in the intact kidney (Fig. 4a)
that were present as rare clusters of tdTomato-labelled cells in our
kidney cultures (Fig. 4b). However, after infection with shRNA-
Tsc2 + Cdkn2a lentiviruses none of these cells contributed to
spheres (Fig. 4c) or tumours (Supplementary Fig. 10h), excluding
that they are the cells of origin of our AML model. These studies
collectively demonstrate that loss of function of Tsc2 and Cdkn2a
in cultured proximal tubule epithelial cells converts them into an
AML-forming neoplastic stem cell.
Guided by these results, we repeated a previously published
experiment involving Pax8-Cre-driven inducible deletion of Tsc1
in adult renal epithelia using Pax8-rtTA;TRE-LC1;Tsc1ﬂ/ﬂ mice33.
As reported, within 2 months of homozygous deletion of Tsc1 in
6–8 week old mice, kidneys developed a severe polycystic
phenotype with intermixed regions of adenoma-like epithelial
proliferation but did not develop renal AMLs (Fig. 5a). All cystic
and adenoma-like regions stained strongly for phosphorylation of
ribosomal protein S6 (Ser240/244), indicative of Tsc1 deletion
(Fig. 5b). Interestingly, however, immunohistochemical analyses
revealed the presence of scattered PMEL positive cells that were
present as single cells or clusters of 2–3 cells (on average 35 sites
per mouse kidney section) within regions of solid or cystic
epithelial proliferation (Fig. 5b). PMEL staining was predomi-
nantly cytoplasmic (Fig. 5c). PMEL positive cells were never
observed in kidneys from wild type mice or Tsc1 heterozygous
mutant mice (Pax8-rtTA;TRE-LC1;Tsc1ﬂ/+). Cysts and adenoma
lesions also showed scattered cells expressing SMA, another
marker of renal AMLs (Fig. 5b). CATHEPSIN K staining was
upregulated in all cells in cysts and adenomas (Fig. 5b), and
CATHEPSIN K protein expression was detected by western
blotting in kidney lysates from homozygous, but not hetero-
zygous Tsc1 mutant mice or wild type mice (Supplementary
Fig. 3i), suggesting that this increase is directly related to Tsc1
deletion and consistent with the fact that almost all cells in
human renal AMLs express CATHEPSIN K27. Given that the
strong hyperproliferative phenotype of Tsc1 homozygous deletion
prevented aging experiments, we generated a cohort of 12 Pax8-
rtTA;TRE-LC1;Tsc1ﬂ/+ heterozygous mutant mice and analysed
them 1 year after inducing gene deletion in 6–8 week old mice. By
histological sectioning of kidneys we identiﬁed 20 cysts (14 were
lined by a single layer of epithelial cells, 6 cysts displayed atypical,
multilayered morphology), 5 small tumours with epithelial
morphology and 28 lesions comprising closely packed cells with
low cytoplasmic volume, often occurring close to blood vessels
(Supplementary Fig. 11). These lesions exhibit a similar
morphology to lesions that were identiﬁed upon Tsc1 deletion
under a ubiquitious promoter and that were proposed to
represent potential precursors of renal AMLs22. Consistent with
this idea, the lesions in our mice harboured many cells that were
positive for phosphorylation of ribosomal protein S6 (Ser240/
244) and some cells that were positive for CATHEPSIN K, SMA,
and more rarely for PMEL (Fig. 5b). Thus, the epithelial-speciﬁc
PAX8-Cre driver appears to recreate a similar phenotype to that
previously described with the ubiquitous Cre driver. These
observations provide in vivo evidence to show that loss of TSC
function in renal epithelial cells can cause the formation of
different lesions that contain cells that express several different
molecular markers of renal AML, consistent with our ex vivo cell
engineering studies.
Epithelial origin of human AMLs. We next sought to determine
the relevance of these mouse-based ﬁndings to human renal
AML. To overcome the senescence barrier associated with loss of
TSC function in primary human cells, we employed RPTECs
immortalised with SV40 large T Antigen and hTERT35 and
infected these cells with four independent shRNA-TSC2
lentiviruses, efﬁciently reducing TSC2 protein abundance (Sup-
plementary Fig. 12a) and inducing the formation of spheres in
non-adherent culture conditions (Supplementary Fig. 12b). These
spheres could be differentiated into epithelial cells, adipocytes and
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glia in culture (Supplementary Fig. 12c). Importantly, while
immortalised RPTECs did not form sub-cutaneous tumours (n=
3 mice), two independent TSC2 hairpins (II and IV) caused the
formation of xenograft tumours (n= 4 mice for each hairpin) that
histologically resembled the characteristic spindle cell, vascular
and adipocyte structures of human renal AMLs, and also dis-
played regions of epithelial structures (Supplementary Fig. 12d).
These tumours expressed the AML marker proteins HMB45,
SMA, VIMENTIN, PDGFRβ and epithelial structures were
positive for E-CADHERIN (Supplementary Fig. 12d). In com-
parison to control cells, shTSC2 spheres exhibited increased
mRNA expression of proximal tubule signature genes and tran-
scription factor encoding genes that were upregulated in spheres
engineered from mouse cells (Supplementary Fig. 12e). Thus,
cultured human renal proximal tubule epithelial cells are also
converted to AML-forming cells by loss of function of TSC2 in
cooperation with abrogation of cellular senescence.
Immunoﬂuorescence staining of seven sporadic human AML
tumours revealed that all tumours contained cells that express
proteins that are expressed in proximal tubular epithelial cells in
the kidney, namely NAPI2A, pan-CD133 and AQP1, but did not
contain cells expressing THP, a marker of epithelial cells of the
thick ascending limb of the loop of Henle (Fig. 6a). Analyses of
mRNA isolated from matched pairs of samples of normal kidney
and AML tumour (n= 7 cases) from parafﬁn-embedded tissue
revealed that all AMLs expressed similar or higher levels of
proximal tubule marker genes (FMO1, CUBN, VIL1) and several
transcription factor-encoding genes identiﬁed from our mouse
studies (TAL1, HNF4A, TFEC) as normal kidney (Fig. 6b). These
ﬁndings corroborate our mouse tumour engineering ﬁndings and
are consistent with the idea that human renal AMLs derive from
renal epithelial cells.
We next obtained a set of isogenic renal AML cell lines to
investigate whether these cells display similarities to our
engineered models. TRI-102 cells are an immortalised (E6/E7
and hTERT) derivative36 of a TSC2 null primary cell culture that
was derived from a human renal AML37. TRI-103 is a derivative
of TRI-102 into which TSC2 expression has been re-introduced36.
Similarly to our engineered cells, TRI-102 but not TRI-103 cells
formed spheres when grown in epithelial medium on non-
adherent plates (Fig. 7a). When grown as adherent cultures, both
TRI-102 and TRI-103 expressed the mesenchymal marker
VIMENTIN, as well as the epithelial marker E-CADHERIN
(Fig. 7b). TRI-102 cells also expressed the proximal tubule marker
proteins CD133 and NAPI2A and the expression of these
proteins was absent or reduced in TRI-103 cells (Fig. 7b). TRI-
102 cells when grown as adherent cells or as spheres expressed
higher mRNA abundance than TRI-103 of the transcription
factors and some of the proximal tubule genes that we identiﬁed
in our engineered systems (Fig. 7c). Finally, TRI-102 but not TRI-
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103 cells could be differentiated into Nile Red, CATHEPSIN K
and PMEL positive cells in appropriate media (Fig. 7d). These
ﬁndings establish that a cell line derived from a human renal
AML have similar renal proximal tubule epithelial features and
differentiation capacities to our engineered cellular systems.
Therapeutic studies using engineered AML models. In a recent
phase 3 clinical trial of the mTORC1 inhibitor everolimus for
large renal AMLs (>3 cm diameter) in TSC patients, 42% of the
patients displayed a reduction in tumour volume of >50% within
one year of treatment20 and this therapy is now a recommended
treatment for these patients. However, once everolimus therapy is
discontinued, AML lesions typically resume growth38,39. The
cellular consequences of everolimus therapy in TSC patient renal
AML tumours have not been able to be studied. To attempt to
address this issue we utilised our engineered AML models.
Everolimus caused a greater inhibition of proliferation of shRNA-
Tsc2/Cdkn2aΔ/Δ sphere-derived cells compared to control
Cdkn2aΔ/Δ kidney cells when grown under adherent cell culture
conditions (Fig. 8a). Everolimus also decreased the number and
size of spheres in non-adherent culture conditions (Fig. 8b–d)
without decreasing cellular viability (Fig. 8e). Rather, everolimus
decreased the proportion of S-phase cells and caused accumula-
tion of cells in the G1 and G2/M cell cycle phases (Fig. 8f). The
addition of everolimus to cellular differentiation experiments did
not alter the ability of shRNA-Tsc2/Cdkn2aΔ/Δ sphere cells to
differentiate into different cellular lineages (Fig. 8g). Everolimus
treatment (10 mg/kg i.p.daily for 2 weeks) of mice harbouring
shRNA-Tsc2/Cdkn2aΔ/Δ allograft tumours blocked tumour
growth and tumours regressed after cessation of treatment but re-
grew after ~3 months (Fig. 8h). This behaviour mimics the
clinical response to mTOR inhibitor therapy. Tumours harvested
during everolimus treatment (Fig. 8i) exhibited no apparent dif-
ferences in histological appearance compared with untreated
tumours (Fig. 8j), nor in the abundance of PMEL immunor-
eactive cells (Fig. 8j, k) but contained fewer proliferating cells as
assessed by BrdU labelling (Fig. 8l, m). While everolimus caused a
3-fold increase in the number of cleaved caspase-3 positive cells, a
marker of apoptosis (Fig. 8n), it should be noted that the fre-
quency of apoptotic cells was very low (<0.1% of cells) and is
therefore unlikely to be the major contributor to the therapeutic
effects of the drug. This observation is consistent with the cell
culture data and demonstrates that mTORC1 inhibition pre-
dominantly induces cell cycle arrest of AML tumour cells, with-
out any obvious effects on cellular differentiation, consistent with
the observed absence of complete cures in renal AML patients.
Discussion
Biallelic loss-of-function mutations inTSC2 and more rarely in
TSC1 appear to represent the key genetic driving events of renal
AMLs19. We show that loss of function of TSC2 in genetic
backgrounds that abrogate senescence and proliferation arrest is
sufﬁcient to convert mouse and human renal proximal tubular
epithelial cells into neoplastic stem cells that give rise to allograft
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or xenograft tumours that reproduce many of the histological and
molecular features of human renal AMLs, providing the ﬁrst
models of AML-like tumours. It should be noted that these
tumours represent ‘models’ as the genetic backgrounds that we
employed in this study to overcome cellular senescence induced
by loss of TSC2 function are apparently not reﬂected in the
genetics of human renal AMLs, for example, genetic mutations or
deletions of TP53, CDKN2A or other senescence regulating
tumour suppressor genes have not been observed in AML
tumours. It remains possible that yet-to-be-identiﬁed
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mechanisms operating at the epigenetic, translational or protein
levels may permit escape from senescence in human renal AML.
In addition, our engineered, sub-cutaneously growing tumours do
not fully reproduce all of the morphological features and growth
patterns seen in human renal AMLs growing in the kidney.
Nonetheless, our studies of our engineered model systems
revealed some new features of human renal AMLs, supporting the
relevance of our models. Our engineered cells exhibit a proximal
tubule gene expression signature, express proximal tubule-speciﬁc
proteins and display upregulation of several transcription factors
that play diverse roles in development and cellular differentiation
programmes. These gene expression signatures and protein
expression pattern are also at least partly present in human renal
AML tumours and in a cell line derived from a renal AML,
arguing that this classic ‘mesenchymal’ tumour might have an
epithelial origin.
While unexpected, these ﬁndings are potentially consistent
with a series of recent studies showing that renal epithelial
cells can exhibit a range of different differentiation capacities. As
part of the process of repair of injured tubules in response to
kidney damage in vivo, renal proximal tubular epithelial cells
adopt a mesenchymal appearance and express several molecular
markers of mesenchymal cells and of stem cells, including the
glycosylated form of CD133, CD24 and high aldehyde dehy-
drogenase activity40–43. Isolation of these cells revealed that they
grow as spheres and that they express a strong ‘stemness’ tran-
scriptional proﬁle43. While not yet proven for cells isolated from
the proximal tubule, isolation of a similarpopulation of CD133/
CD24-expressing parietal epithelial cells from the Bowman’s
capsule of the glomerulus revealed that these cells could be dif-
ferentiated in culture into several types of renal epithelial cells,
adipocytes, osteoblasts, endothelial cells and neuronal cells, sug-
gestive of a multi-potent progenitor cell phenotype44. Thus, at
least some and potentially all renal epithelial cells appear to
exhibit a degree of cellular plasticity and can adopt progenitor or
stem cell properties under certain circumstances45. Our obser-
vations that renal epithelium-speciﬁc heterozygous and homo-
zygous deletion of Tsc1 in the mouse kidney causes the emergence
of lesions in which at least some cells express molecular markers
of renal AML is consistent with the notion that epithelial cells
in vivo might have the capacity to become transformed to gen-
erate renal AMLs. Our genetically engineered tumour models
provide the ﬁrst experimental tools to further explore this idea
and to deﬁne the molecular pathways that govern renal AML
tumour biology, for example to assess the potential functions
of upregulated transcription factors in causing cellular
transformation and stemness. Our studies on the mechanistic
basis of everolimus therapy provide proof-of-principle that these
experimental models might also facilitate the future identiﬁcation
and pre-clinical validation of new therapeutic approaches for
renal AMLs.
An interesting unanswered question is why mutation of TSC1
or TSC2 in humans predominantly causes the development of
renal AMLs, renal cysts and more rarely of renal carcinomas,
whereas Tsc1 or Tsc2 mutation in rats or mice causes renal cysts,
adenomas and carcinomas, but does not lead to the formation of
renal AMLs21. It is possible that the strong phenotypic effect of
Tsc1 or Tsc2 deletion in causing epithelial hyperproliferation in
the mouse kidney means that AMLs do not have the necessary
time to develop in mouse models. Alternatively, we speculate that
our cell culture setting in some way reproduces speciﬁc micro-
environmental conditions, or niches, that are abundant in human
kidneys but rare in mouse kidneys in vivo, and that these speciﬁc
conditions are necessary for the formation of AMLs. One possi-
bility could be the apparent enhanced rate of loss and replace-
ment of renal epithelial cells in human nephrons compared to
mouse nephrons that is believed to underlie the apparent ‘spon-
taneous’ epithelial to mesenchymal transition and acquisition of
features of stemness in normal human kidneys but not in rodent
kidneys41. Finally, it is possible that AML development requires
additional, yet-to-be-identiﬁed genetic or epigenetic alterations
that cooperate with loss of TSC function to promote the transi-
tion of an epithelial cell to an AML stem cell.
Renal AML belongs to a broader class of tumours termed
PEComas that are named after the common presence of peri-
vascular epithelioid cells (PEC). PEComas also include AMLs that
form in other organs, lymphangioleiomyomatosis of the lung,
clear-cell sugar tumour of the lung, clear-cell myomelanocytic
tumour of the falciform ligament and other rare clear-cell
tumours found at other anatomical sites46. PEComas represent a
biological enigma as they share several cellular and molecular
features and frequently involve TSC mutation, but the cell type(s)
of origin of all of these tumours remains unknown; there is no
known normal anatomical counterpart of the perivascular epi-
thelioid tumour cell. By presenting evidence that suggests that the
cell of origin of renal AMLs could be an epithelial cell, our studies
suggest a new paradigm in the understanding of the biology of
this disease and also suggest that epithelial cells in other organs
might potentially represent the cells of origin of other types of
PEComas. In view of our results, the classiﬁcation of renal AML
as a PEComamight be a misnomer and the current pathological
terminology might need be reconsidered.
Methods
Mouse strains. The following mouse strains were utilised in this study: SCID/beige
mutant mice (C.B-17/CrHsd-PrkdcscidLystbg-1) and C57BL/6JOlaHsd mice were from
Fig. 8 Everolimus induces cell cycle arrest in AML tumour allografts. a Sulforhodamine B cell number assay of total populations of Cdkn2aΔ/Δ primary
kidney cells infected with empty shRNA (shRNA-Ctrl/Cdkn2aΔ/Δ) or with shRNA targeting Tsc2 (shRNA-Tsc2/Cdkn2aΔ/Δ)and two single cell-derived
sphere clones (shRNA-Tsc2/Cdkn2aΔ/Δ SC3 and SC6) treated with everolimus for 7 days. Cells were grown under adherent conditions and values
represent A540 ratios of treated to untreated cells. b Phase contrast images of shRNA-Tsc2/Cdkn2aΔ/Δ spheres formed in suspension culture conditions in
the presence or absence of everolimus (1.6 nM, 48 h). Scale bars: 50 μm. c–f Number c, diameter d, cellular viability e and cell cycle phase ﬂow cytometry
analysis f (x-axis propidium iodide (PI) staining, y-axis α-BrdU staining) of shRNA-Tsc2/Cdkn2aΔ/Δ sphere cells after 48 h everolimus (1.6 nM) treatment.
Cells were incubated with BrdU (30 μM) for 12 h prior to harvesting. g mRNA abundance of the indicated genes in shRNA-Tsc2/Cdkn2a spheres
differentiated in the presence or absence of everolimus (1.6 nM, 48 h). h, i Long term h and short term i growth of shRNA-Tsc2/Cdkn2aΔ/Δ AML allograft
tumours treated with saline (control) or everolimus (10mg/kg i.p. daily for 2 weeks). The timepoints of starting and stopping therapy are indicated. Images
of tumours from each group at the end points of the two experiments are shown. Scale bar: 1 cm. j Representative histological images (H&E staining) and
PMEL(HMB45) immunoﬂuorescence stainings of shRNA-Tsc2/Cdkn2aΔ/Δ AML-like allograft tumours from the experiment shown in i. k Percentage of
PMEL positive cells in shRNA-Tsc2/Cdkn2aΔ/Δ AML-like allograft tumours from the experiment shown in i. l Immunoﬂuorescence staining using α-BrdU
antibody (red) and DAPI staining (blue), arrowheads highlight positive nuclei. Proliferating cells were labelled by injection of mice with BrdU (80 μg/g body
weight i.p.) 32, 24 and 8 h prior to harvesting tumours. m Quantiﬁcation of percentage of nuclei in tumours from i that were labelled with BrdU.
n Quantiﬁcation of number of cells per ×40 microscopy ﬁeld staining positively for cleaved caspase 3 in tumours from i. All graphs depict mean± s.d.
Student’s t test, n= 3. ∗P< 0.05; ∗∗P< 0.01; ∗∗∗P< 0.001
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Harlan Laboratories. Cdkn2aﬂ/ﬂ (FVB;129P2-Cdkn2atm2Brn/Cnrm)47 were from
EMMA (EM:00407). Sox10-Cre mice have been previously described48. Tsc1ﬂ/ﬂ
(Tsc1tm1Djk/J)24 mice were from Jackson Laboratory (005680). Ai14 td-Tomato
reporter mice (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J)34 were from Jackson
Laboratory (007914). Pax8-rtTA;TRE-LC133 mice were obtained from Prof. Car-
sten Wagner, University of Zurich and were intercrossed with Tsc1ﬂ/ﬂ mice.
Approximately 6–8 week old were exposed to doxyxycline (5 mg/ml) in drinking
water supplemented with 5% sucrose for 5 days. Animals were subsequently kept
on normal drinking water for 2 months. All mouse experiments were approved by
the Veterinary Ofﬁce of the Canton of Zurich under the licence 06/2013. No
statistical method was used to predetermine sample size. The experiments were not
randomised and the investigator was not blinded to the genotype of mice.
Allograft and xenograft experiments. For allograft and xenograft experiments,
SCID/beige mice were anesthetised and injected subcutaneously with 5 × 106 cells
suspended in 50% Matrigel (BD, no.354230). Tumour growth was monitored
throughout the experiment and tumour size measured with calipers every 3 days.
Everolimus treatment (10 mg/kg i.p.) of mice harbouring AML allograft tumours
was performed daily for 2 weeks.
Cell culture. Primary MEFs were isolated from E13.5 embryos from WT (C57BL/
6) or Cdkn2aﬂ/ﬂ strains, cultured in DMEM plus 10% fetal bovine serum (FBS) in
cell-culture incubators supplemented with 5% CO2 and maintained at 5% O2.
Murine primary kidney cells were isolated and cultured in complete K-1 culture
medium (DMEM-F12 medium (D6421, Sigma) supplemented with 0.5% FBS,
25 mM Glutamine, 5 mg/ml insulin, 1.25 ng/ml prostagladin E1, 34 pg/ml 3,3,5
Triiodothyronine, 5 mg/ml human Apo-transferrin, 1.75 ng/ml sodium selenite, 20
ng/ml Hydrocortisone and 25 ng/ml murine epidermal growth factor) as descri-
bed49. For non-adherent cultures to induce sphere formation, kidney cells (2 × 103)
were plated in ultra-low attachment culture plates (Corning, 3471) and incubated
in complete K-1 culture medium. The spheroids appeared after ~7–10 days in
culture. Spheres were dissociated into single cells using Accutase (Gibco,
A-11105–01) for replating or for other assays. Human Renal Proximal Tubular
Epithelial Cells (RPTEC) TH1 cell line is derived from primary human renal
proximal tubule epithelial cells immortalised by two lentiviral vectors carrying the
human telomerase (hTERT) and the SV40 T antigen35. These cells, as well as
B16F1 cells, were cultured in DMEM plus 10% FBS in cell culture incubators at 37 °
C, 5% CO2 and 5% O2. The TRI-102 and TRI-103 cell lines were kindly provided
by Elizabeth Henske (Brigham and Women’s Hospital, Boston) and cultured in K1
medium in cell culture incubators at 37 °C, 5% CO2 and 5% O2. RPTEC TH1, TRI-
102 and TRI-103 cells tested negatively for mycoplasma and were validated based
on resistance to selection markers (Neo or Zeo) as well as by western blotting for
exogenously expressed proteins (SV40 Large T-antigen).
Adipocyte differentiation: Cells obtained from spheres were cultured in DMEM
high Glucose, 10% FBS, supplemented with 0.5 mM IBMX, 0.25 μM
Dexamethasone, 1 μg/mL Insulin and 2 μM Rosiglitarone. 48 h later medium was
changed to DMEM high Glucose, 10% FBS, supplemented with 1 μg/mL Insulin for
48 h. After this treatment, cells were cultured in DMEM high Glucose, 10% FBS
without supplements for 7 days.
Neuralcrest differentiation: Cells obtained from spheres were cultured in
DMEM-F12 medium, 5% FBS, supplemented with 160 nM TPA (12-O-
tetradecanoyl phorbol-13-acetate), 50 ng/mL mSCF (Stem cell factor, mouse,
recombinant), 100 nM ET-3 (Endothelin 3, human), 25 ng/mL bFGF (Fibroblast
growth factor-basic, human), 100 ng/mL α-MSH (α-Melanocyte stimulating
hormone) and 1 nM Dexamethasone for 10 days.
Osteoblast differentiation: Cells obtained from spheres were cultured in DMEM
high Glucose, 10% FBS, supplemented with 0.2 mM ascorbic acid, 0.25 μM
Dexamethasone and 10 mM β-Glycerol phosphate for 14 days.
Epithelial differentiation: Cells obtained from spheres were cultured in complete
K-1 media for 10 days.
Viral infections. MEFs and primary kidney cells were infected with adenoviruses
expressing GFP (Vector Biolabs, 1060) or Cre-GFP (Vector Biolabs, 1700), lenti-
viruses (LKO.1) expressing non-silencing hairpin (Addgene, 10879) or shRNA
against Tsc1 (Sigma, TRCN0000238187) or shRNA against Tsc2 (Sigma,
TRCN0000306244). For lentiviral-mediated knockdown of Cdkn2a and Tsc2, we
generated a MuLEvector50 containing U6 promoter-driven expression of shRNA
against Cdkn2a, 7SK promoter-driven expression of shRNA against Tsc2 and PGK
promoter-driven expression of puromycin resistance. Human RPTECs were
infected with lentiviruses expressing non-silencing hairpin (Addgene, 1864) or four
different shRNAs against TSC2 (Sigma, TRCN0000295896, TRCN000010455,
TRCN000010454 and TRCN000040182). All cells were incubated overnight in
virus-containing medium in the presence of 4 μg/ml polybrene (Sigma-Aldrich, no.
H9268). Drug selection was performed 48 h after transduction using 4 μg/ml of
puromycin. Cells were isolated from dissected tumours by digestion for 1 h at 37 °C
with 1 mg/ml collagenase type II (Gibco, Life Technologies), washed twice with
PBS, and cultured in DMEM plus 10% FBS.
Cellular assays. Cellular senescence was evaluated using the Senescence kit
(Calbiochem QIA 117). For proliferation assays, cells were seeded at 2 × 105 cells
per 6 cm dish in triplicate dishes and counted after 3 days before reseeding at the
same density for the next passage. All proliferation assays shown are representative
of at least three independent experiments. Cell viability within the spheres treated
with and without everolimus was measured with a Trypan Blue viability assay.
Drug Assays. Transformed primary kidney cells were seeded at a density of 2 ×
103 cells per well on a 96 well plate. After attachment of the cells, everolimus was
individually added at different concentrations and medium changed every two days
to ensure addition of new drug. Cells were ﬁxed after 7 days in 5% w/v tri-
chloracetic acid and stained in 0.057% w/v Sulforhodamine B (SRB) solution and
air-dried. SRB was solubilized by incubation in the 10 mM Tris base solution (pH
10.5) and OD was measured at 540 nm in a micro-plate reader.shRNA-Tsc2/
Cdkn2aΔ/Δ spheres were cultured in the presence or absence of everolimus
(1.6 nM) for 48 h.
Western blotting, antibody stainings and other stainings. Western blotting,
immunoﬂuorescence or immunohistochemistry were conducted using antibodies
against the following proteins or epitopes: β-ACTIN (Sigma-Aldrich, A2228, WB
1:5000), TSC1 (Cell Signaling Technology, 4906 s, WB 1:1000), TSC2 (Cell Sig-
naling Technology, 3990s, WB 1:1000), p16 (Santa Cruz Biotechnology, sc-1207,
WB 1:200), p19 (Santa Cruz Biotechnology, sc-32748, WB 1:200), p53 (Novocastra,
NCL-p53-CM5p, WB 1:500), HIF-1α (Novus Biologicals, NB100-105, WB 1:500),
GLUT1 (Abcam, ab14683, WB 1:2500), ribosomal protein S6 (Cell Signaling
Technology 2217 s, WB 1:1000), phospho Ser240/244 ribosomal protein S6 (Cell
Signaling Technology, 2215 s, WB 1:1000. IHC 1:200), 4E-BP1 (Cell Signaling
Technology, 9644 s, WB 1:1000), phosphoThr37/46 4E-BP1 (Cell Signaling Tech-
nology, 2855 s, WB 1:1000), CD31 (Abcam, ab28364, IF 1:100), SMA (Abcam,
ab5694, IHC 1.200, IF 1:100), antibody cocktail HMB45 + DT101 + BC199
(Abcam, ab732, IF 1:100), PMEL/gp100(HMB45) (Abcam, ab137078, WB 1:1000,
IHC 1:100, ICC 1:250),HMB45 (DAKO A/S, M0634, IHC 1:200), PDGFRβ
(Abcam, ab32570, IHC 1:100), VIMENTIN (Cell Signaling Technology, 5741,WB
1:1000, IF 1:200, ICC 1:200), E-CADHERIN (BD Bioscience, 610181, WB
1:1000and Abcam, ab11512, IHC 1:50, ICC 1:100), pan-CYTOKERATIN (BMA
Biomedicals AG,T1302,IHC 1:100), GFAP (Abcam, ab7260, ICC 1:5000),
NAPI2A51 (IF 1:100, ICC 1:100), AQP1 (Abcam, ab15080, IF 1:200), THP (Santa
Cruz Biotechnology, sc-20631, IF 1:200), CD133(Abnova, PAB12663, IF 1:100, ICC
1:100), CD10 (Novocastra Laboratories Ltd,NCL-L-CD10-270, IHC 1:200), RCC
(Ventana-Cell Marque, 760-4273, IHC 1:200),RFP (Bioconcept, 600-401-379, IF
1:200, ICC 1:200), BrdU (Merck Milipore, MAB3510, IF 1:200), cleaved CASPASE-
3 (Cell Signaling, 9661, IF 1:400), S100 (Abcam, ab183979, IHC 1:100), NG2
(Abcam, ab129051, IHC 1:100), MELAN-A (Santa Cruz Biotechnology, sc-20032,
IF 1:50, ICC 1:50), CATHEPSIN K (Abcam, ab19027, WB 1:1000, IHC 1:200, ICC
1:200), MiTF (Abcam, ab20663, WB 1:1000, ICC 1:200), PAX8 (Protein Tech,
10366-1-AP, IHC 1:800), MYC (Abcam, ab32072, WB 1:1000).Validations of the
primary antibodies are provided on the manufacturer’s websites or in the refer-
enced citations. Full scans of all western blots presented in this study are shown in
Supplementary Fig. 13.
Characterisation of adipocytes was performed using Nile Red (Molecular Probes
TM) or Oil-Red-O staining. Cells were ﬁxed in 10% formalin at room temperature
for 1 h and after washing them in 60% isopropanol and drying them, Oil-Red-O
solution (0.5% Oil-Red-O solution) was added for 2 h. Cells were washed with
distilled water and counterstained with hematoxylin.
RNA analyses. Total RNA was extracted from cells and tissues using NucleoSpin
RNA Kit (Machery-Nagel) or RNeasy Mini Kit (Quiagen) and cDNA synthesis was
done with random hexamer primers and Ready-To-Go You-Prime First-Strand
Beads (GE Healthcare). Primers used for real time PCR analyses are listed in
Supplementary Table 1. For deep sequencing, RNA samples were sequenced using
an IluminaHiSeq 2000 sequencer at the Functional Genomics Center Zurich
(FGCZ). GSEA analyses were conducted using the Molecular Signatures Database
(http://software.broadinstitute.org/gsea/msigdb/index.jsp).
Flow cytometry. Flow cytometry analysis of the mesenchymal stem cell markers
was performed as described in mouse multipotent mesenchymal stromal cell
marker antibody panel protocol (R&D systems, SC018). Everolimus treated and
untreated sphere cells were incubated with BrdU (30 μM) for 12 h prior to har-
vesting and cell-cycle analysis by ﬂow cytometrywas conducted as described52.
Analyses of human AMLs. Tissues samples for immunoﬂuorescence and real-
time quantitative PCR were obtained at the University Hospital of Zurich (Zurich,
Switzerland). The study was approved by the local ethics commission (reference
number KEK-ZH-Nr. 2014-0604) with informed patient consent. RNA was
extracted from punches of parafﬁn-embedded renal AML tumours and normal
kidney tissue from the same patient.
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Electron microscopy. Tissue culture samples were ﬁxed in 2.5% buffered glutar-
aldehyde overnight, postﬁxed in 1% osmium tetroxide for 2 h, dehydrated in
graded alcohols, incubated in pure propylenoxide and then propylenoxide-Epon
mix and then embedded in Epon. The sections were cut with diamond knives on an
ultramicrotome (Ultracut E, Reichert Jung, 90 nm sections), stained with uranyl
acetate and lead citrate, and examined using a Hitachi TEM type H-7650 electron
microscope.
Statistics. Statistical signiﬁcance was determined by two-tailed Student’s test, with
a P value <0.05 considered to be statistically signiﬁcant.
Data availability. All data relevant to this publication are provided in the Figures
and Supplementary Information.
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